Emory University

The United States Government As Represented by the Department of Veterans Affairs

Children's Healthcare of Atlanta, Inc.

Lily Yang

Hui Mao

Xiangxue Guo

Shuming Nie

Xiaohu Gao

Wei Chen

Jack Arbiser

Lei Zhu

Yuancheng Li

Xiang Hong Peng

Xiangxue Gao

Erica Bozeman

This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen activator receptor (uPAR) insulin-like growth factor 1 receptor (IGF1R), EGFR, HER2, and/or other member of the ErbB family of receptors. In certain embodiments, the molecule that binds a cancer marker is an amino terminal fragment of uPA or variant capable of binding uPAR and/or IGF1 or variant capable of binding IGF1R. In certain embodiments, the toxic polypeptide is a bacterial exotoxin.

Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

Hyaluronic acid nanoparticles comprising NADPH oxidases inhibitors and uses in treating cancer

This disclosure relates to palladium hyaluronic acid particles such as dibenzylideneacetone palladium hyaluronic acid particles. In certain embodiments, this disclosure relates to methods of managing cancer or angiogenic conditions using particles disclosed herein and pharmaceutical compositions comprising the same. In certain embodiments, an objective of this disclosure is hyaluronic acid targeting of CD44, a tumor stem cell marker. In certain embodiments, this disclosure relates to treatment with hyaluronic acid palladium particles disclosed herein for depleting CD44 cells.

Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions

This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

Targeted protease compositions and uses related thereto

This disclosure relates to peptides and nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.

Nanoparticles having molecules that bind or block PD-L1 and uses in treating cancer

This disclosure relates to polymer coatings with desirable anti-fouling properties. In certain embodiments, polymers are coated on particles which allow for conjugation with targeting moieties. In certain embodiments, the particles are nanoparticles with targeting moieties that bind with tumor associated antigens.

Anti-fouling saline and siloxane coated particles, substrates, polymers and uses related thereto

This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents.

Nanoparticles carrying nucleic acid cassettes for expressing RNA

A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a magnetic iron oxide nanoparticle, a hydrophobic protection structure including at least an amphiphilic copolymer, wherein the hydrophobic protection structure encapsulates the magnetic iron oxide nanoparticle, and at least one amino-terminal fragment (ATF) peptide or epidermal growth factor receptor (EGFR) antibody conjugated to the amphiphilic copolymer.

Nanostructures, methods of synthesizing thereof, and methods of use thereof

A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a nanospecies, a hydrophobic protection structure including at least one compound selected from a capping ligand, an amphiphilic copolymer, and combinations thereof, wherein the hydrophobic protection structure encapsulates the nanospecies, and at least one histidine-tagged peptide or protein conjugated to the hydrophobic protection structure, wherein the at least one histidine-tagged peptide or protein has at least one binding site.

Growing community of inventors

Atlanta, GA, United States of America

Lily Yang